First Wave BioPharma, Inc. stock is up 6.42% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 March’s closed higher than February.
First Wave BioPharma, Inc. engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!